Details of the Drug Combinations

General Information of This Drug (ID: DMR4HIW)

Drug Name
Insulin-glargine   DMR4HIW
Synonyms Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Non-insulin dependent diabetes 5A11 Approved [2]
Malaria 1F40-1F45 Phase 3 [3]
Type-1 diabetes 5A10 Phase 3 [4]
Type-2 diabetes 5A11 Application submitted [5]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Insulin-lispro + Insulin-glargine DCWCQQE Insulin-lispro Diabetes Mellitus, Type 2 [6]
Insulin-lispro + Insulin-glargine DCYNJ5C Insulin-lispro Diabetes Mellitus, Type 1 [7]
Lixisenatide + Insulin-glargine DCUI33J Lixisenatide Type-2 diabetes [8]
Insulin-glargine + Insulin-aspart DC3WH4E Insulin-aspart Type 2 Diabetes [9]
Insulin-glargine + Insulin-aspart DCD9TWJ Insulin-aspart Hyperglycemia Steroid-induced [10]
Insulin-glargine + Exenatide DCJLJC7 Exenatide Type 2 Diabetes [11]
Sitagliptin + Insulin-glargine DCY47RE Sitagliptin Type 2 Diabetes [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
2 Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
3 ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT01215955) Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
7 ClinicalTrials.gov (NCT01454284) A Study in Participants With Type I Diabetes Mellitus
8 Clinical pipeline report, company report or official report of Sanofi.
9 ClinicalTrials.gov (NCT03336528) Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
10 ClinicalTrials.gov (NCT03511521) Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
11 ClinicalTrials.gov (NCT02455076) Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
12 ClinicalTrials.gov (NCT01845831) Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes